C12N 2770/20022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/20022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 386 US grants and 1,153 published applications in this corpus.
Search patents in C12N- Granted patents
- 386
- Published applications
- 1,153
- Assignees
- 701
- Inventors
- 3,434
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 6 | 0 |
| 1998 | 6 | 0 |
| 1999 | 7 | 0 |
| 2000 | 15 | 0 |
| 2001 | 7 | 1 |
| 2002 | 8 | 5 |
| 2003 | 5 | 4 |
| 2004 | 0 | 8 |
| 2005 | 1 | 23 |
| 2006 | 6 | 32 |
| 2007 | 3 | 23 |
| 2008 | 11 | 11 |
| 2009 | 14 | 18 |
| 2010 | 8 | 8 |
| 2011 | 5 | 11 |
| 2012 | 1 | 8 |
| 2013 | 8 | 2 |
| 2014 | 7 | 3 |
| 2015 | 4 | 10 |
| 2016 | 1 | 7 |
| 2017 | 7 | 9 |
| 2018 | 8 | 7 |
| 2019 | 6 | 11 |
| 2020 | 11 | 18 |
| 2021 | 25 | 74 |
| 2022 | 38 | 111 |
| 2023 | 32 | 265 |
| 2024 | 36 | 236 |
| 2025 | 51 | 173 |
| 2026 | 34 | 75 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- High-potency SARS coronavirus 2 antigen and vaccine composition comprising same29 Sep 2026US 12,747,268 B2Korea Research Institute of Chemical Technology
- Follicular helper T (TFH) cells specific to SARS-COV-2 virus15 Sep 2026US 12,734,232 B2The University of Osaka
- AAV5-based vaccine against SARS-CoV-215 Sep 2026US 12,734,235 B2
- Vaccine using M2/BM2-deficient influenza vectors8 Sep 2026US 12,728,160 B2FluGen, Inc.
- Spike Protein Based Genetic Vaccines8 Oct 2026US 2026/0306616 A1University of Maryland, Baltimore
- Replicon dna, cloning vector, screening kit, screening method, anti-nobecov-irus agent, beta-coronavirus proliferation inhibitor, pan beta-coronavirus inhibitor, virus proliferation inhibitor, hepatitis c virus proliferation inhibitor, and method for screening therapeutic agent for viral infectious disease8 Oct 2026US 2026/0308206 A1Kagoshima University
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Coronavirus s2 immunogens1 Oct 2026US 2026/0295034 A1The Scripps Research Institute
- Vaccine with reduced anti-vector antigenicity24 Sep 2026US 2026/0284178 A1
Most cited
By later US patents
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Method of inducing an immune response with a live Venezuelan Equine Encephalitis virus expressing a heterologous immunogen123US 5,643,576 AThe University of North Carolina at Chapel Hill · 1997
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001
- Attenuating mutations in Venezuelan Equine Encephalitis virus63US 5,505,947 AThe University of North Carolina at Chapel Hill · 1996